Results 251 to 260 of about 81,723 (303)
Corrigendum to: Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. [PDF]
J Crohns Colitiseuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Janus kinase inhibitors: efficacy and safety
Current Opinion in Rheumatology, 2023Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire +2 more sources
Janus kinase inhibitors for alopecia areata
Journal of the American Academy of Dermatology, 2023Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire +2 more sources
Investigational Janus kinase inhibitors
Expert Opinion on Investigational Drugs, 2013Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire +2 more sources
Oral Janus kinase inhibitors for atopic dermatitis
Annals of Allergy, Asthma & Immunology, 2023Atopic dermatitis (AD) is one of the most common inflammatory skin conditions. The pathogenesis of AD involves skin barrier disruption and immune activation of T-helper (TH)2 and TH22 and varying degrees of TH1 and TH17 activation in various patient subtypes.
Daniela, Mikhaylov +3 more
openaire +2 more sources
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
Expert Opinion on Investigational Drugs, 2023JAK inhibitors (JAKis), used in the treatment of myelofibrosis, have entered standard treatment, providing significant improvements in spleen size and symptom burden. Although splenomegaly provides a reduction and some improvement in cytopenia, there is still a way to go. Novel JAKis are being investigated to overcome barriers to treatment access, such
Yildiz Ipek +3 more
openaire +2 more sources
2017
To control gene expression, cytokines and other extracellular molecules utilize the Janus kinase (JAK) and signal transducers and activators of transcription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders.
Andrew Kim, Bruce Strober
openaire +1 more source
To control gene expression, cytokines and other extracellular molecules utilize the Janus kinase (JAK) and signal transducers and activators of transcription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders.
Andrew Kim, Bruce Strober
openaire +1 more source
[Pharmacology of Janus kinase inhibitors].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2019Modern dermatotherapy is dominated by the development of various biologicals and small molecules. Janus kinase inhibitors (JAKi) form a novel class of small molecular synthetic compounds inhibiting the intracellular signal transduction of cytokine receptors. Cytokines are key mediators in the pathophysiology of numerous inflammatory skin diseases. Many
F, Solimani, F J, Hilke, K, Ghoreschi
openaire +2 more sources
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)
Bioorganic & Medicinal Chemistry Letters, 2009A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs). Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide). Details of synthesis and SAR studies of these compounds are reported.
Burns, Christopher J. +22 more
openaire +3 more sources